Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers

BACKGROUND: COX-2 inhibitors can be effective for acute migraine, but none is supplied in a rapidly absorbed, ready-to-use oral liquid formulation. DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Clinical studies with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Arindam, Shenoy, Srinivas, Gautam, Anirudh, Munjal, Sagar, Niu, Jing, Gopalakrishnan, Mathangi, Gobburru, Joga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602059/
https://www.ncbi.nlm.nih.gov/pubmed/28748412
http://dx.doi.org/10.1007/s40261-017-0548-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602059/
https://www.ncbi.nlm.nih.gov/pubmed/28748412
http://dx.doi.org/10.1007/s40261-017-0548-6

Ejemplares similares